The United Laboratories International Holdings Limited provided unaudited consolidated earnings guidance for the year ended December 31, 2017. The board of directors of the company informed the shareholders of the Company and the potential investors that, based on the unaudited consolidated management accounts of the company for the year ended 31 December 2017 prepared in accordance with Hong Kong Financial Reporting Standards, the group's unaudited annual results for the year 2017 is expected to record a profit of approximately RMB 80 million, while the loss for the year 2016 was approximately RMB 272 million (as restated due to change in presentation currency). Turning from loss to profit is mainly attributable to increase in the sales prices of intermediate and bulk medicine products; net foreign exchange gain recorded during current year; and the loss on fair value change on investment properties being offset.